Compounds > lumin
Page last updated: 2024-11-13

lumin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lumin: structure given in first source; RN refers to dichloride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23305342
MeSH IDM0148238

Synonyms (5)

Synonym
lumin
4,4'-(3-(2-(1-ethyl-4-(1h)-quinolinylidene)ethylidene))propenylene bis(1-ethylquinolinium)
quinolinium, 4,4'-(3-((1-ethyl-4(1h)-quinolinylidene)ethylidene)-1-propene-1,3-diyl)bis(1-ethyl-, dichloride
1-ethyl-4-[(1e,3e,5e)-1-(1-ethylquinolin-1-ium-4-yl)-5-(1-ethylquinolin-4-ylidene)penta-1,3-dien-3-yl]quinolin-1-ium;dichloride
1-ethyl-4-[(1e,3z,5z)-1-(1-ethylquinolin-1-ium-4-yl)-5-(1-ethylquinolin-4-ylidene)penta-1,3-dien-3-yl]quinolin-1-ium;dichloride

Research Excerpts

Overview

Lumin is a potent cell-activating agent and a photosensitizer. It is characterized by typical absorption peaks at 670 and 770 nm.

ExcerptReferenceRelevance
"Lumin is a potent cell-activating agent and a photosensitizer characterized by typical absorption peaks at 670 and 770 nm."( Photodynamic efficiency of macrophage activity using a photosensitizer, lumin, with near-IR laser light for photoimmunotherapy of a cancer.
Mito, K, 1996)		1.25
"Lumin is a potent cell-activating agent and a photosensitizer characterized by absorption peaks at 670 nm and 770 nm. "( A needle type therapeutic system incorporating laser light and lumin for immunotherapy of cancer growing in deep organs.
Mito, K, )		1.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's3 (30.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.59 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index201.15 (26.88)
Search Engine Supply Index2.52 (0.95)

This Compound (92.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		2101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
carbocyanines
Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.		2.0510cyanine dye;
organic iodide salt		fluorochrome
platonin
platonin: RN given refers to diiodide; structure in first source		210
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Plasmodium
[description not available]		02.610
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		07.610
Herpes Simplex Virus Infection
[description not available]		02.0510
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		02.0510
Adenocarcinoma, Basal Cell
[description not available]		01.9910
Cancer of Lung
[description not available]		01.9910
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9910
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9910
Cancer of Colon
[description not available]		0210
Experimental Neoplasms
[description not available]		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Libman-Sacks Disease
[description not available]		01.9710
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		01.9710
Delayed Hypersensitivity
[description not available]		01.9710